Tevogen Bio Holdings Inc.
- Open
- 6.01
- Day high
- 6.65
- Day low
- 6.01
- Prev close
- 5.66
- Volume
- 10K
- Mkt cap
- $28M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -2.8
- P/S
- —
- Yield
- —
- Per share
- —
Tevogen Bio Holdings Inc. (TVGN) is a Healthcare company listed on NASDAQ. The stock is down 91% over the past year.
Tevogen Bio Holdings Inc. (TVGN) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TVGN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | $-2.64 | $-1.61 | +39.0% | — | — |
| Mar 31, 2026 | $-1.50 | $-1.20 | +20.0% | — | — |
| Nov 14, 2025 | $-0.06 | $-0.03 | +50.7% | — | — |
| Aug 19, 2025 | $-0.05 | $-0.03 | +40.0% | — | — |
| Apr 2, 2025 | $-0.03 | $-0.05 | -56.1% | $396586 | — |
| Nov 19, 2024 | — | $-0.03 | — | — | — |
| Aug 14, 2024 | — | $-0.06 | — | — | — |
| May 27, 2024 | — | $0.08 | — | — | — |
| Dec 30, 2023 | — | $-0.01 | — | — | — |
TVGN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 17, 2026 | Flomenberg Nealofficer: See Remarks | Sell | 501 | $6.40 |
| Mar 17, 2026 | Flomenberg Nealofficer: See Remarks | Sell | 452 | $7.26 |
| Mar 17, 2026 | Flomenberg Nealofficer: See Remarks | Sell | 19 | $7.75 |
| Jul 1, 2025 | Desai Kirtiofficer: Chief Financial Officer | Grant | 750,000 | — |
| Jul 1, 2025 | Saadi Ryan H.director, 10 percent owner, officer: Chief Executive Officer | Grant | 8,000,000 | — |
| Jul 1, 2025 | Khan Sadiqofficer: Chief Commercial Officer | Grant | 200,000 | — |
| Jul 1, 2025 | Flomenberg Nealofficer: See Remarks | Grant | 300,000 | — |
| Jun 9, 2025 | Saadi Ryan H.director, 10 percent owner, officer: Chief Executive Officer | Sell | 1,438,206 | $1.23 |
| Mar 14, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 232,968 | $1.09 |
| Mar 11, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 70,384 | $1.09 |
| Mar 11, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 70,252 | $1.05 |
| Mar 11, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 71,273 | $1.14 |
| Mar 6, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 88,519 | $1.10 |
| Mar 6, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 110,659 | $1.21 |
| Mar 6, 2025 | Flomenberg Nealofficer: See Remarks | Sell | 14,639 | $1.28 |
Source: TVGN SEC Form 4 filings, latest Mar 17, 2026. For informational purposes only — not investment advice.
See the full TVGN insider & 13F page →Tevogen Bio Holdings Inc. company profile
Overview
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is a clinical-stage biotechnology company founded in 2021 and based in Warren, New Jersey. The company went public in January 2022 and specializes in developing off-the-shelf precision T cell therapeutics targeting diseases in virology, oncology, and neurology. Tevogen represents a relatively new entrant in the immunotherapy space, focusing on creating standardized T cell treatments that can be manufactured at scale and administered to patients without the need for personalized cell engineering.
Business
Tevogen Bio operates in the biotechnology sector, specifically within the immunotherapy subsegment that focuses on T cell therapeutics. T cells are a type of white blood cell that plays a crucial role in the immune system's ability to fight infections and cancer. Traditional T cell therapies, such as CAR-T treatments, require extracting a patient's own T cells, genetically modifying them in a laboratory, and then reinfusing them back into the same patient - a process that is time-consuming, expensive, and highly personalized. Tevogen's approach differs significantly by developing off-the-shelf precision T cell therapeutics. This means they create standardized T cell products that can be manufactured in advance and stored, then administered to multiple patients without requiring individual customization. The company's platform technology identifies and isolates T cells from healthy donors that have already been naturally trained to recognize specific disease targets. The company's lead investigational product is TVGN 489, which is designed to treat acute-risk COVID-19 patients and certain patients suffering from long COVID syndrome. Long COVID refers to persistent symptoms that continue for weeks or months after the initial COVID-19 infection has resolved. TVGN 489 contains T cells that have been pre-selected for their ability to recognize and attack SARS-CoV-2, the virus that causes COVID-19. Beyond virology applications, Tevogen is also developing T cell therapeutics for oncology (cancer treatment) and neurology applications, though these programs appear to be in earlier stages of development compared to their COVID-19 focused lead product.
Revenue model
As a clinical-stage biotechnology company, Tevogen currently generates minimal revenue and operates primarily on a research and development model funded by investor capital. The company reported only $396,586 in revenue for Q4 2024, likely from research collaborations or licensing agreements, while maintaining zero revenue in most other recent quarters. Tevogen's future business model will depend on successfully advancing its T cell therapeutics through clinical trials and obtaining regulatory approval. Once approved, the company would generate revenue through several potential channels: 1. Direct product sales to hospitals and healthcare systems, 2. Licensing agreements with pharmaceutical partners for commercialization rights, 3. Manufacturing and supply agreements for their off-the-shelf products. The company's competitive advantage lies in its off-the-shelf approach, which could potentially offer faster treatment delivery and lower costs compared to personalized T cell therapies. However, several factors could significantly impact margins and profitability. Positive factors include the scalability of their manufacturing platform, potential premium pricing for innovative immunotherapies, and the large addressable market for viral infections and cancer treatments. Negative factors include intense competition from established pharmaceutical companies, high regulatory hurdles typical in biotechnology, significant manufacturing costs for cell-based therapies, and the risk of clinical trial failures that could eliminate entire revenue streams. The company's success is particularly sensitive to clinical trial outcomes, regulatory approval timelines, and their ability to demonstrate superior efficacy and safety compared to existing treatments. Given the early-stage nature of their pipeline, Tevogen faces the typical biotech challenge of high cash burn rates with uncertain revenue generation timelines.
Competitive moat
Tevogen Bio's competitive moat appears relatively narrow at this early stage of development. The company's primary potential advantage lies in its off-the-shelf T cell platform technology, which could offer faster treatment delivery and potentially lower costs compared to personalized CAR-T therapies. However, this technological approach is not entirely unique, as several other biotechnology companies are pursuing similar allogeneic (donor-derived) T cell strategies. The company's intellectual property portfolio around their T cell selection and manufacturing processes could provide some protection, but the strength of these patents and their ability to create meaningful barriers to entry remain unproven. Tevogen's focus on viral targets, particularly COVID-19, may face challenges as the acute pandemic phase has subsided and market demand has evolved. Significant competitive threats emerge from multiple directions. Large pharmaceutical companies with substantially greater resources are actively developing competing immunotherapies. Established players in the CAR-T space, such as Gilead's Kite Pharma and Bristol Myers Squibb's Juno Therapeutics, have proven manufacturing capabilities and regulatory expertise that could be applied to off-the-shelf approaches. Additionally, the broader competitive landscape includes not just other T cell therapies but also monoclonal antibodies, small molecule drugs, and other treatment modalities targeting similar indications. The company's moat is further weakened by its limited clinical data, lack of approved products, and dependence on a relatively narrow pipeline. Without established market presence, proven efficacy, or significant manufacturing scale, Tevogen currently lacks the defensive characteristics typically associated with strong competitive moats in biotechnology. The company's future moat will largely depend on clinical trial success, regulatory approvals, and their ability to establish manufacturing and commercial partnerships before competitors capture significant market share.
Risks & safety
Tevogen Bio presents significant financial risk with a very narrow margin of safety, typical of early-stage biotechnology companies. • Cash burn and solvency risk: The company burned approximately $12 million in operating cash flow during 2024, with only $1.3 million in cash and short-term investments as of Q4 2024. At current burn rates, the company faces immediate liquidity challenges and will likely require additional financing within months. • Balance sheet weakness: Total current liabilities of $9.0 million significantly exceed current assets of $2.4 million, resulting in a current ratio of 0.26. The company shows negative shareholders' equity, indicating liabilities exceed total assets. • Valuation metrics: With minimal revenue ($396,586 in Q4 2024) and substantial losses (net loss of $13.7 million in 2024), traditional valuation metrics are largely meaningless. The company trades on speculative potential rather than fundamental value. • Debt considerations: While the company doesn't carry significant traditional debt, its negative working capital and immediate funding needs create substantial financial pressure. • Other risks: As a clinical-stage biotech with no approved products, the company faces binary outcomes from clinical trials, regulatory risks, and potential total loss of investment if development programs fail.
Recent development
Based on available financial data, Tevogen Bio's recent development has been characterized by continued advancement of their clinical programs while facing significant financial constraints. The company has maintained focus on their lead product TVGN 489 for COVID-19 applications, though specific clinical trial milestones and regulatory interactions are not detailed in the available financial statements. The most notable recent development has been the company's deteriorating financial position, with cash reserves declining from $2.3 million in Q3 2024 to $1.3 million by Q4 2024. This trend indicates accelerating cash burn and suggests the company has likely undertaken additional financing activities or cost reduction measures not fully reflected in the available quarterly data. Revenue generation remains minimal, with the company reporting $396,586 in Q4 2024 revenue compared to zero revenue in most other recent quarters. This suggests possible research collaboration income or milestone payments, though the irregular nature indicates these are not recurring revenue streams. The company's operational focus appears to remain on advancing their T cell therapeutic platform, though the lack of detailed earnings call transcripts limits visibility into specific strategic initiatives, partnership developments, or clinical trial progress during this period.
TVGN company profile · for informational purposes only — not investment advice.
Track TVGN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free